Feng Huang Wang·2026-03-06 14:35Group 1 - The core point of the article is the launch of Pemafibrate, a novel lipid-lowering drug by Japan's Kowa Company, on Meituan's self-operated pharmacy platform, marking its first appearance online [1] - Pemafibrate is the world's first highly selective PPARα modulator, demonstrating over 2500 times stronger activation efficacy compared to the active metabolite of Fenofibrate, thus offering high selectivity, low dosage, and fewer adverse reactions [1] - The drug is expected to be officially approved in China by April 2025 for the treatment of dyslipidemia, with Harbin Yuheng Pharmaceutical acting as its promotional agent, highlighting the significant market interest in its launch [1] Group 2 - Meituan's self-operated pharmacy has over 1300 types of imported original research drugs and boasts a delivery service where over 90% of orders can be delivered on the same or next day [2] - The platform has become a crucial launchpad for new and specialty drugs, indicating its growing importance in the pharmaceutical e-commerce sector [2] - The increasing demand for lipid-lowering medications is underscored by over 12 million users searching for such products on Meituan in the past six months, reflecting a substantial health need in the market [1]